Loading...
XASXMEM
Market cap6mUSD
Dec 23, Last price  
0.01AUD
1D
0.00%
1Q
-33.33%
IPO
-99.99%
Name

Memphasys Ltd

Chart & Performance

D1W1MN
XASX:MEM chart
P/E
—
P/S
177.10
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
38.80%
Rev. gr., 5y
-13.40%
Revenues
60k
+290.35%
1,610,8922,167,1815,374,4581,799,7102,549,415918,654850,85579,90063,9600000211,48327,14815,37160,000
Net income
-4m
L+30.55%
-5,496,190-2,739,0433,291,709-6,563,463-4,924,039-1,841,920-3,842,140-2,360,019-2,174,721-1,999,891-401,159-1,044,578-1,133,879-1,486,432-2,081,964-3,402,618-4,442,021
CFO
-3m
L+129.72%
-3,998,047400,615-2,628,865-1,696,642-655,087-987,970-941,638-2,422,179-1,270,580-1,228,595-738,419-707,472120,19547,249311,817-1,406,669-3,231,375
Earnings
Feb 24, 2025

Profile

Memphasys Limited develops, manufactures, and sells cell and protein separation devices, and related consumables for the healthcare, veterinary, and biotechnology market sectors in Australia. It primarily develops Felix, a novel automated device for quickly and gently separating high quality sperm from a raw semen sample for use in human IVF procedures. In addition, the company's product pipeline include ROSA, a rapid oxidative stress assay; Samson Device, rapid equine pregnancy prediction assay; SemPort, a central lab human semen analysis from distantly located donors; and AI-Port. An ambient temperature semen transport device used for animal artificial insemination. Memphasys Limited was formerly known as NuSep Holdings Limited and changed its name to Memphasys Limited in July 2016. The company was incorporated in 2006 and is based in Homebush, Australia.
URL
https://www.memphasys.com/
IPO date
May 14, 2007
Employees
24
Domiciled in
AU
Incorporated in
AU

Valuation

Title
AUD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑062023‑062022‑062021‑062020‑062019‑062018‑062017‑062016‑062015‑06
Income
Revenues
60
290.35%
15
-43.38%
27
-87.16%
Cost of revenue
3,610
3,031
2,586
Unusual Expense (Income)
NOPBT
(3,550)
(3,016)
(2,559)
NOPBT Margin
Operating Taxes
1
(2)
Tax Rate
NOPAT
(3,550)
(3,016)
(2,559)
Net income
(4,442)
30.55%
(3,403)
63.43%
(2,082)
40.06%
Dividends
Dividend yield
Proceeds from repurchase of equity
3,353
2,793
1,015
BB yield
-20.73%
-20.44%
-2.96%
Debt
Debt current
4,473
4,658
3,659
Long-term debt
732
3,429
1,903
Deferred revenue
Other long-term liabilities
2
1
1,858
Net debt
4,913
7,380
5,176
Cash flow
Cash from operating activities
(3,231)
(1,407)
312
CAPEX
(638)
(1,822)
(2,923)
Cash from investing activities
(711)
(1,977)
(3,078)
Cash from financing activities
3,540
3,752
1,032
FCF
(2,042)
(2,686)
(2,079)
Balance
Cash
278
681
312
Long term investments
14
26
74
Excess cash
289
706
384
Stockholders' equity
6,838
7,385
7,647
Invested Capital
11,361
13,052
12,823
ROIC
ROCE
EV
Common stock shares outstanding
2,310,465
975,891
858,134
Price
0.01
-50.00%
0.01
-65.00%
0.04
-37.50%
Market cap
16,173
18.38%
13,662
-60.20%
34,325
-35.22%
EV
21,087
21,043
39,502
EBITDA
(2,833)
(2,403)
(2,435)
EV/EBITDA
Interest
417
428
570
Interest/NOPBT